Filing Flows › Maxcyte (MXCT) › Product sales revenue
Maxcyte (MXCT) Product sales revenue by quarter
Maxcyte's Product sales revenue was $4.1M in Q2 2026 (second quarter 2026), +13% from Q1 2026. Over the last 7 quarters it ranged from $3.6M (Q1 2026) to $5.8M (Q4 2024).
| Quarter | Product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.1M | +13% | -22% |
| Q1 2026 | $3.6M | -12% | -32% |
| Q4 2025 | $4.2M | +5% | -28% |
| Q3 2025 | $4.0M | -25% | — |
| Q2 2025 | $5.3M | -0.9% | — |
| Q1 2025 | $5.3M | -8% | — |
| Q4 2024 | $5.8M | — | — |
Q2 2026 at a glance
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Maxcyte's Product sales revenue?
Maxcyte's Product sales revenue was $4.1M in Q2 2026 (second quarter 2026), +13% from Q1 2026.
How has Maxcyte's Product sales revenue changed?
Over the last 7 quarters it ranged from $3.6M (Q1 2026) to $5.8M (Q4 2024).